Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.

摘要: Genetic factors regulate bone mineral density (BMD) and possibly the development of osteoporosis. An association between estrogen receptor (ER) polymorphism, BMD, postmenopausal hormone replacement therapy (HRT) has not been established. Therefore, we studied influence ER genotype on BMD before after a 5-year HRT in placebo-controlled, population-based, randomized group 322 early women. The participants were into two treatment groups: (n = 145) received sequential combination 2 mg estradiol valerate 1 CPA with or without vitamin D3, 100-300 IU + 500 calcium lactate/day (equal to 93 Ca2+), non-HRT 177) lactate, alone IU/day. PvuII restriction fragment length polymorphism (RFLP) ERalpha was determined using polymerase chain reaction (PCR). BMDs lumbar spine (L2-4) proximal femur measured by dual-energy X-ray absorptiometry (DXA). At baseline, there no significant differences femoral neck three groups (PP, Pp, pp). After 5 years, remained unaltered that increased 1.7% group, whereas both decreased 4-5% group. did modulate change during follow-up. In contrast, non-HRT-group more subjects genotypes PP (6.4%) Pp (5.2%) than pp (2.9%) (p 0.002). relative changes similar all groups. Thus HRT, associated smaller decrease genotypes. Long-term seemed eliminate genotype-related BMD. We conclude may have greater risk relatively fast loss menopause those they preferentially derive benefit from HRT.